Marc Fellous

Princeton Microwave Technology (United States) — United States

Medicine · Health Sciences

36h-index4.8kcitations153works1.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(25), T-cell and B-cell Immunology(24), Immune Cell Function and Interaction(23), Monoclonal and Polyclonal Antibodies Research(22), Reproductive Biology and Fertility(14)

Publications153 total

Abstract C046: Natural history and prognostic value of <i>TP53</i> Y220C mutation in advanced solid tumors: A real-world study
Molecular Cancer Therapeutics·2025· 1 cited
PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a <i>TP53</i> Y220C mutation
Future Oncology·2025· 2 citedOpen Access
PYNNACLE phase II trial assessing rezatapopt (PC14586), a selective p53 reactivator, in patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation
Gynecologic Oncology·2025
Abstract P3-12-27: Phase 1 Analysis from the PYNNACLE Phase 1/2 Study of Rezatapopt in the Subgroup of Patients with Advanced Breast Cancer Harboring a TP53 Y220C Mutation
Clinical Cancer Research·2025· 1 cited
PYNNACLE phase 2 clinical trial of rezatapopt in patients with advanced solid tumors harboring a <i>TP53</i> Y220C mutation.
Journal of Clinical Oncology·2025· 1 cited
150TiP PYNNACLE phase II study of rezatapopt in patients with advanced solid tumors, including breast cancers, and a TP53 Y220C mutation
ESMO Open·2025· 1 citedOpen Access
Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation
Gynecologic Oncology·2024· 1 cited
691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation
Annals of Oncology·2024· 4 citedOpen Access
Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a <i>TP53</i> <i>Y220C</i> mutation
Molecular Cancer Therapeutics·2023· 10 cited
Abstract CT545: Variability in <i>NTRK</i> gene fusions does not appear to impact response to larotrectinib
Cancer Research·2022
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
BMC Cancer·2022· 10 citedOpen Access
Overall survival (OS) of patients with TRK fusion–positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD).
Journal of Clinical Oncology·2022· 1 cited
HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours
Neuro-Oncology·2022· 1 citedOpen Access
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
Journal of Clinical Oncology·2022· 6 cited
Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Journal of Clinical Oncology·2022· 4 cited
Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.
Journal of Clinical Oncology·2022· 2 cited
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
Journal of Clinical Oncology·2022· 15 cited
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
Journal of Clinical Oncology·2022· 11 cited
SO-31 Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An expanded dataset
Annals of Oncology·2022· 10 citedOpen Access
61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
Annals of Oncology·2022Open Access
page 1 of 8Next →

Frequent Co-authors

Sandra Pellegrini(7), Reiner A. Veitia(6), Laura Evelia Torres Velázquez(4), Gabriel Gachelin(4), Joëlle Wiels(3), Giovanna Barbieri(3), Gilles Uzé(3), Frédéric Rosa(3), Rosa Bono(3), J Dausset(3), Thomas Tursz(3), Jorge Kalil(3), Philippe Dubois(3), David Wallach(2), Michel Revel(2), Maria Cristina Gauzzi(2), K. E. Mogensen(2), Jesper Zeuthen(2), Philip Avner(2), Malek Kamoun(2)